Novos new drug CagriSema, which combines Wegovys active ingredient with an amylin analog, is in a Phase 3 trial, and Lilly is working on an amylin-based drug thats in Phase 2 trials
Finding: 14% reduction in major adverse cardiovascular events (MACE) with oral semaglutide
Traditional insurance sometimes covers brand name GLP-1s when prescribed through in person clinics for obesity or diabetes, but coverage is highly variable and often requires prior authorization and specific BMI or comorbidity criteria
While some patients may experience relief within days, others might need several weeks for their bodies to adjust fully to the medication
Its development has proceeded through phase 1, phase 2, and phase 3 trials, most prominently as the fixed-dose CagriSema combination with semaglutide, which has generated late-stage efficacy data but remains under regulatory evaluation rather than in approved clinical use
Early clinical trials suggest it may achieve slightly stronger fat loss compared to Tirzepatide